MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/s0140-6736(23)00329-x

Медицинская библиотека · Lancet (London, England) · 2023

Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.

de Masson Adèle, Beylot-Barry Marie, Ram-Wolff Caroline, Mear Jean-Baptiste, Dalle Stéphane, d'Incan Michel, Ingen-Housz-Oro Saskia, Orvain Corentin, Abraham Julie, Dereure Olivier, Charbonnier Amandine, Cornillon Jérôme, Longvert Christine, Barete Stéphane, Boulinguez Serge, Wierzbicka-Hainaut Ewa, Aubin François, Rubio Marie-Thérèse, Bernard Marc, Schmidt-Tanguy Aline, Houot Roch, Pham-Ledard Anne, Michonneau David, Brice Pauline, Labussière-Wallet Hélène, Bouaziz Jean-David, Grange Florent, Moins-Teisserenc Hélène, Jondeau Katayoun, Michel Laurence, Mourah Samia, Battistella Maxime, Daguindau Etienne, Loschi Michael, Picard Alexandra, Franck Nathalie, Maillard Natacha, Huynh Anne, Nguyen Stéphanie, Marçais Ambroise, Chaby Guillaume, Ceballos Patrice, Le Corre Yannick, Maury Sébastien, Bay Jacques-Olivier, Adamski Henri, Bachy Emmanuel, Forcade Edouard, Socié Gérard, Bagot Martine, Chevret Sylvie, Peffault de Latour Régis, CUTALLO Investigators, Groupe Français d'Etude des Lymphomes Cutanés, Société Française de Greffe de Moëlle et Thérapie Cellulaire

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Advanced-stage cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and fatal diseases. Case series have suggested that allogeneic haematopoietic stem cell transplantation (HSCT) might improve the prognosis of advanced-stage CTCLs. The objective of this study was to investigate the effect of allogeneic HSCT compared with non-HSCT therapy on the outcome of individuals with advanced-stage CTCLs.

METHODS

In this prospective, multicentre, matched controlled trial, conducted at 30 hospitals, participants with advanced CTCLs were allocated treatment: if they had an available compatible related donor they were assigned to allogeneic HSCT, or if not they were allocated to non-allogeneic HSCT therapy. Key inclusion criteria were participants aged 18-70 years, with advanced stage mycosis fungoides or Sézary syndrome, and at least one poor prognostic criteria. Participants were excluded if they were not in complete or partial remission of the disease. Propensity score 1:1 matching with replacement (ie, that each participant treated with HSCT was matched to the participant with the closest propensity score treated with non-HSCT therapy, even if they had already been matched) was used to handle confounding factors, with the balance of covariate distribution between HSCT and non-HSCT groups assessed using standardised mean differences. The primary endpoint was progression-free survival in the matched intention-to-treat population. This trial is registered with ClinicalTrials.gov (NCT02520908), and is currently active but not recruiting.

FINDINGS: From June 1, 2016, to March 3, 2022, total of 99 participants were enrolled at 17 centres in France. Participants with a sibling or matched unrelated donor were assigned to allogeneic HSCT (HSCT group, n=55 [56%]) and participants without a donor were assigned to non-allogeneic HSCT treatment (non-HSCT group, n=44 [44%]). The median follow-up among survivors was 12·6 months (IQR 11·0-35·2). In the HSCT group, 51 participants (93%) were 1:1 matched to participants from the non-HSCT group. In the intention-to-treat analysis, median progression-free survival was significantly longer in the HSCT group (9·0 months [95% CI 6·6-30·5]) than in the non-HSCT group (3·0 months [2·0-6·3]), with a hazard ratio of 0·38 (95% CI 0·21-0·69; p<0·0001). In the per-protocol population, 40 participants (78%) in the HSCT group had 101 serious events and 29 participants (67%) in the non-HSCT group had 70 serious adverse events. The most common serious adverse event other than graft-versus-host disease in both groups was infections, occurring in 30 participants (59%) in the HSCT group and in 19 participants (44%) in the non-HSCT group.

INTERPRETATION: Allogeneic HSCT was associated with significantly longer progression-free survival in participants with advanced-stage CTCLs. These results indicate that allogeneic HSCT treatment should be made available to individuals with high-risk, advanced-stage mycosis fungoides or Sézary syndrome who achieve pre-transplant disease remission.

FUNDING: French Ministry of Health, National Cancer Institute, Programme Hospitalier de Recherche Clinique en Cancérologie.

Для цитирования: de Masson Adèle, Beylot-Barry Marie, Ram-Wolff Caroline, Mear Jean-Baptiste, Dalle Stéphane, d'Incan Michel, Ingen-Housz-Oro Saskia, Orvain Corentin, Abraham Julie, Dereure Olivier, Charbonnier Amandine, Cornillon Jérôme, Longvert Christine, Barete Stéphane, Boulinguez Serge, Wierzbicka-Hainaut Ewa, Aubin François, Rubio Marie-Thérèse, Bernard Marc, Schmidt-Tanguy Aline, Houot Roch, Pham-Ledard Anne, Michonneau David, Brice Pauline, Labussière-Wallet Hélène, Bouaziz Jean-David, Grange Florent, Moins-Teisserenc Hélène, Jondeau Katayoun, Michel Laurence, Mourah Samia, Battistella Maxime, Daguindau Etienne, Loschi Michael, Picard Alexandra, Franck Nathalie, Maillard Natacha, Huynh Anne, Nguyen Stéphanie, Marçais Ambroise, Chaby Guillaume, Ceballos Patrice, Le Corre Yannick, Maury Sébastien, Bay Jacques-Olivier, Adamski Henri, Bachy Emmanuel, Forcade Edouard, Socié Gérard, Bagot Martine, Chevret Sylvie, Peffault de Latour Régis, CUTALLO Investigators, Groupe Français d'Etude des Lymphomes Cutanés, Société Française de Greffe de Moëlle et Thérapie Cellulaire. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.. Lancet (London, England). 2023. DOI: 10.1016/s0140-6736(23)00329-x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.